Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model

Cécile Hérate (1) , Romain Marlin (1) , Franck Touret (2) , Nathalie Dereuddre-Bosquet (1) , Flora Donati (3, 4) , Francis Relouzat (1) , Laura Junges (1) , Mathilde Galhaut (1) , Océane Dehan (3, 4) , Quentin Sconosciutti (1) , Antoine Nougairède (2) , Xavier de Lamballerie (2) , Sylvie van der Werf (3, 4) , Roger Le Grand (1)

1 IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
2 UVE - Unité des Virus Emergents
3 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
4 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challenge model.

Domains: Life Sciences [q-bio]

Cécile Hérate, Romain Marlin, Franck Touret, Nathalie Dereuddre-Bosquet, Flora Donati, et al.. Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model. 2023. ⟨pasteur-04073340⟩